In the latest session, Protagonist Therapeutics Inc (NASDAQ: PTGX) closed at $32.15 up 5.83% from its previous closing price of $30.38. In other words, the price has increased by $+1.77 from its previous closing price. On the day, 913505 shares were traded. PTGX stock price reached its highest trading level at $33.34 during the session, while it also had its lowest trading level at $30.25.
Ratios:
For a deeper understanding of Protagonist Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.71 and its Current Ratio is at 16.71. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, CapitalOne on October 30, 2023, initiated with a Overweight rating and assigned the stock a target price of $32.
On August 25, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $21.JMP Securities initiated its Mkt Outperform rating on August 25, 2022, with a $21 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 01 when PATEL DINESH V PH D sold 30,000 shares for $31.62 per share. The transaction valued at 948,600 led to the insider holds 574,590 shares of the business.
Ali Asif sold 14,248 shares of PTGX for $459,318 on Mar 01. The Chief Financial Officer now owns 38,397 shares after completing the transaction at $32.24 per share. On Mar 01, another insider, Waddill William D., who serves as the Director of the company, sold 12,975 shares for $31.34 each. As a result, the insider received 406,636 and left with 12,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 1.85B and an Enterprise Value of 1.51B. For the stock, the TTM Price-to-Sale (P/S) ratio is 31.22 while its Price-to-Book (P/B) ratio in mrq is 5.51. Its current Enterprise Value per Revenue stands at 25.20 whereas that against EBITDA is -16.74.
Stock Price History:
Over the past 52 weeks, PTGX has reached a high of $31.40, while it has fallen to a 52-week low of $13.72. The 50-Day Moving Average of the stock is 25.60, while the 200-Day Moving Average is calculated to be 21.51.
Shares Statistics:
For the past three months, PTGX has traded an average of 809.05K shares per day and 514.52k over the past ten days. A total of 57.71M shares are outstanding, with a floating share count of 54.71M. Insiders hold about 6.15% of the company’s shares, while institutions hold 95.74% stake in the company. Shares short for PTGX as of Feb 15, 2024 were 2.78M with a Short Ratio of 3.44, compared to 2.55M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.82% and a Short% of Float of 4.88%.
Earnings Estimates
There are 5 different market analysts currently analyzing its stock. On average, analysts expect EPS of $2.22 for the current quarter, with a high estimate of $4.58 and a low estimate of -$0.62, while EPS last year was -$0.67. The consensus estimate for the next quarter is -$0.61, with high estimates of -$0.54 and low estimates of -$0.66.
Analysts are recommending an EPS of between $2.92 and -$2.71 for the fiscal current year, implying an average EPS of $0.79. EPS for the following year is -$0.81, with 5 analysts recommending between $2.14 and -$3.27.
Revenue Estimates
Based on 3 analysts’ estimates, the company’s revenue will be $183.33M in the next fiscal year. The high estimate is $330M and the low estimate is $75M. The average revenue growth estimate for next year is up 77.40% from the average revenue estimate for this year.
